#regdanvimab

Collection of regdanvimab news, found 10 news.

BPOM permits Paxlovid usage for treating COVID-19 patients

BPOM permits Paxlovid usage for treating COVID-19 patients

  • 18th July 2022

The National Agency of Drug and Food Control (BPOM), on Sunday, issued emergency use authorization (EUA) for Paxlovid ...

Emergency use authorization issued for four COVID-19 therapeutic drugs

Emergency use authorization issued for four COVID-19 therapeutic drugs

  • 30th June 2022

The National Agency of Drug and Food Control (BPOM) has issued emergency use authorization (EUA) for Favipiravir, ...

COVID-19: BPOM issues EUA for Molnupiravir

COVID-19: BPOM issues EUA for Molnupiravir

  • 14th January 2022

The Indonesian Food and Drug Supervisory Agency (BPOM) has issued emergency-use authorization (EUA) for COVID-19 ...

Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

  • 3rd January 2022

Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the ...

BPOM aims to start indigenous vaccine production by 2022 second half

BPOM aims to start indigenous vaccine production by 2022 second half

  • 29th December 2021

Head of the National Agency of Drug and Food Control (BPOM), Penny Lukito, has said that the agency is aiming to start ...

Celltrion’s monoclonal antibody treatment regdanvimab, approved by the European Commission for the treatment of COVID-19

Celltrion’s monoclonal antibody treatment regdanvimab, approved by the European Commission for the treatment of COVID-19

  • 15th November 2021

Celltrion Group announced today that the European Commission (EC) has approved Regkirona (regdanvimab, CT-P59), one of ...

Celltrion receives CHMP positive opinion for regdanvimab (CT-P59) as one of the first monoclonal antibodies recommended as a treatment for COVID-19 by the CHMP

Celltrion receives CHMP positive opinion for regdanvimab (CT-P59) as one of the first monoclonal antibodies recommended as a treatment for COVID-19 by the CHMP

  • 12th November 2021

Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for ...

Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)

Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)

  • 20th September 2021

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a ...

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

  • 15th June 2021

infected animals was confirmed with a clinical dosage of regdanvimab (CT-P59)1 Incheon, South Korea--(Antara/Business ...

Celltrion confirms neutralising potency against emerging SARS-CoV-2 variants with anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59)

Celltrion confirms neutralising potency against emerging SARS-CoV-2 variants with anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59)

  • 20th May 2021

Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed ...